Citations

Mayo Clinic

Showing 10 of 108572 citations.

Liver Transplantation for Hepatocellular Carcinoma: A Narrative Review and A Glimpse into The Future
Liu, Hao , Li, Xingjie , Xiao, Yao , Humar, Abhinav , Sethi, Vrishketan

Seminars in Liver Disease | January 12, 2024 | Volume: 44 | Issue: 01 | Pages: 079-098

10.1055/a-2242-7543 | PMID 38211621 Get It

Liver transplantation (LT) is a highly effective treatment for carefully selected patients with hepatocellular carcinoma (HCC). In this review, we explored the development of LT selection criteria and organ allocation policies, comparing original data to underscore their historical progression into the intricate task of quantitatively estimating pre- and post-LT survivals. We emphasized the role of biomarkers such as serum alpha-fetoprotein, Des-gamma-carboxy-prothrombin, circulating tumor cells, and circulating tumor DNA in predicting patient outcomes. Additionally, we examined the transplant-associated survival benefits and the difficulties in accurately calculating these benefits. We also reviewed recent advancements in targeted therapy and checkpoint inhibitors for advanced, inoperable HCC and projected their integration into LT for HCC. We further discussed the growing use of living donor liver transplants in the United States and compared its outcomes with those of deceased donor liver transplants. Furthermore, we examined the progress in machine perfusion techniques, which have shown potential in improving patient outcomes and enlarging the donor pool. These advancements present opportunities to enhance LT patient survivals, refine selection criteria, establish new priority metrics, develop innovative bridging and downstaging strategies, and formulate redesigned LT strategies for HCC treatments.
Identification of a rare [Gγ(Aγδβ)0] ‐thalassemia using tandem mass spectrometry
Bellad, Anikha , Rangiah, Kannan , Appadorai, Pragalatha Kumar, Lokanatha, Hemalatha, Murthy, Pradeep Rudra, Gowdra, Aruna, Pandey, Akhilesh , Sathe, Gajanan , Pandey, Akhilesh , Bellad, Anikha , Sathe, Gajanan , Dey, Gourav

PROTEOMICS | January 11, 2024 | Volume: 24 | Issue: 14 | Pages: No page available

10.1002/pmic.202300495 | PMID 38212249 Get It

AbstractThalassemias are a group of inherited monogenic disorders characterized by defects in the synthesis of one or more of the globin chain subunits of the hemoglobin tetramer. Delta‐beta (δβ‐) thalassemia has large deletions in the β globin gene cluster involving δ‐ and β‐globin genes, leading to absent or reduced synthesis of both δ‐ and β‐globin chains. Here, we used direct globin‐chain analysis using tandem mass spectrometry for the diagnosis of δβ‐thalassemia. Two cases from unrelated families were recruited for the study based on clinical and hematological evaluation. Peptides obtained after trypsin digestion of proteins extracted from red blood cell pellets from two affected individuals and their parents were analyzed using liquid chromatography‐tandem mass spectrometry (LC‐MS/MS). Mass spectrometric analysis revealed a severe reduction in δ, β, and Aγ globin proteins with increased Gγ globin protein in the affected individuals. The diagnosis of Gγ(Aγδβ)0 ‐thalassemia in the homozygous state in the affected individuals and in the heterozygous state in the parents was made from our results. The diagnosis was confirmed at the genetic level using multiplex ligation‐dependent probe amplification (MLPA). Our findings demonstrate the utility of direct globin protein quantitation using LC‐MS/MS to quantify individual globin proteins reflecting changes in globin production. This approach can be utilized for accurate and timely diagnosis of hemoglobinopathies, including rare variants, where existing diagnostic methods provide inconclusive results.
CCR5 and CCL5 gene expression in colorectal cancer: comprehensive profiling and clinical value
Battaglin, Francesca , Millstein, Joshua , Yang, Yan , Xiu, Joanne , Arai, Hiroyuki , Wang, Jingyuan , Innocenti, Federico , Kawanishi, Natsuko , Lenz, Annika , Algaze, Sandra , Zhang, Wu, Khoukaz, Taline, Torres, Evanthia T. Roussos , Seeber, Andreas , Abraham, Jim , Shields, Anthony F. , Goldberg, Richard M. , Lenz, Heinz‐Josef , Arai, Hiroyuki , Lou, Emil , Lenz, Heinz-Josef , Baca, Yasmine , Wang, Jingyuan , Ou, Fang‐Shu , Mumenthaler, Shannon M. , Jayachandran, Priya , Soni, Shivani , Lou, Emil , Philip, Philip A. , Weinberg, Benjamin A. , Marshall, John L , Venook, Alan P. , Korn, Wolfgang Michael

Journal for ImmunoTherapy of Cancer | January 11, 2024 | Volume: 12 | Issue: 1 | Pages: e007939

10.1136/jitc-2023-007939 | PMID 38212126 Get It

Background The C-C motif chemokine receptor 5 (CCR5)/C-C motif chemokine ligand 5 (CCL5) axis plays a major role in colorectal cancer (CRC). We aimed to characterize the molecular features associated with CCR5 / CCL5 expression in CRC and to determine whether CCR5 / CCL5 levels could impact treatment outcomes. Methods 7604 CRCs tested with NextGen Sequencing on DNA and RNA were analyzed. Molecular features were evaluated according to CCR5 and CCL5 tumor gene expression quartiles. The impact on treatment outcomes was assessed in two cohorts, including 6341 real-world patients and 429 patients from the Cancer and Leukemia Group B (CALGB)/SWOG 80405 trial. Results CCR5 / CCL5 expression was higher in right-sided versus left-sided tumors, and positively associated with consensus molecular subtypes 1 and 4. Higher CCR5 / CCL5 expression was associated with higher tumor mutational burden, deficiency in mismatch repair and programmed cell death ligand 1 (PD-L1) levels. Additionally, high CCR5 / CCL5 were associated with higher immune cell infiltration in the tumor microenvironment (TME) of MMR proficient tumors. Ingenuity pathway analysis revealed upregulation of the programmed cell death protein 1 (PD-1)/PD-L1 cancer immunotherapy pathway, phosphatase and tensin homolog (PTEN) and peroxisome proliferator-activated receptors (PPAR) signaling, and cytotoxic T-lymphocyte antigen 4 (CTLA-4) signaling in cytotoxic T lymphocytes, whereas several inflammation-related pathways were downregulated. Low CCR5 / CCL5 expression was associated with increased benefit from cetuximab-FOLFOX treatment in the CALGB/SWOG 80405 trial, where significant treatment interaction was observed with biologic agents and chemotherapy backbone. Conclusions Our data show a strong association between CCR5/CCL5 gene expression and distinct molecular features, gene expression profiles, TME cell infiltration, and treatment benefit in CRC. Targeting the CCR5/CCL5 axis may have clinical applications in selected CRC subgroups and may play a key role in developing and deploying strategies to modulate the immune TME for CRC treatment.
Common design and data elements reported in active mechanical thrombectomy trials focusing on distal medium vessel occlusions and minor strokes: a systematic review
Bilgin, Cem , Bolsegui, Marisabel Linares , Ghozy, Sherief , Hassankhani, Amir , Kobeissi, Hassan , Jabal, Mohamed Sobhi , Gupta, Rishabh , Rubeis, Gianluca De , Kadirvel, Ramanathan , Brinjikji, Waleed , Saba, Luca , Kallmes, David F. , De Rubeis, Gianluca , Ghozy, Sherief , Kobeissi, Hassan , Saba, Luca

Journal of NeuroInterventional Surgery | January 11, 2024 | Volume: 17 | Issue: 5 | Pages: 530-538

10.1136/jnis-2023-021073 | PMID 38212110 Get It

Background Distal medium vessel occlusions (DMVOs) and minor strokes represent emerging frontiers in mechanical thrombectomy (MT). Although several randomized clinical trials (RCTs) are underway, the design characteristics of these trials and the specific questions they aim to address have not been extensively explored. This current study sought to investigate the design and data elements reported in active prospective DMVO and minor stroke studies. Methods The ClinicalTrials.gov database was searched for ongoing prospective studies assessing the role of MT in patients with DMVOs or minor strokes. The Nested Knowledge AutoLit platform was utilized to categorize reported outcomes and inclusion/exclusion criteria. Frequencies of reported data elements were extracted from study protocols. Results A total of 10 (8 DMVO and 2 minor stroke) studies enrolling 3520 patients were included. All DMVO studies employ different criteria regarding target occlusion locations. Five DMVO studies use stent retrievers as the first-line thrombectomy technique (62.5%, 5/8), while three studies allow any MT techniques, generally at the operator’s discretion. Four DMVO studies permit intravenous thrombolysis (IVT) utilization in both intervention and control arms (50%, 4/8). The DISTALS trial excludes patients receiving IVT, while the DUSK trial and Tigertriever registry only enroll patients who are ineligible for IVT or for whom IVT failed to achieve reperfusion. DMVO studies exhibit notable heterogeneity in symptom onset duration thresholds for inclusion (<6 hours: 2 studies; <12 hours: 2 studies; <24 hours: 3 studies). Minor stroke trials employ similar inclusion criteria and outcome measures except for symptom duration thresholds for inclusion (8 hours for ENDOLOW and 23 hours for MOSTE). Conclusions There is considerable heterogeneity among active DMVO trials regarding potential target DMVO locations and time thresholds for inclusion based on the last known well time. Furthermore, our review indicates that the utility of aspiration thrombectomy in DMVOs and the advantages of MT without IVT over IVT alone will remain largely unexplored even after completion of active DMVO trials.
The Landscape of Pediatric Radiation Oncology in Nigeria
Joseph, Adedayo , Akinsete, Adeseye Michael , Lasebikan, Nwamaka , Awofeso, Opeyemi , Oladipo, Aishat , Ajose, Azeezat , Ojo, Oluwatimileyin, Merrell, Kenneth W. , Ngwa, Wilfred, Puthoff, David , Akinsete, Adeseye M , Lasebikan, Nwamaka N , Awofeso, Opeyemi M , Ajose, Azeezat O , Merrell, Kenneth W , Ngwa, Wilfred , Onitilo, Adedayo A , Adeneye, Samuel Olaolu , Ngwa, Wilfred

JCO Global Oncology | January 11, 2024 | Volume: No volume available | Issue: 10 | Pages: No page available

10.1200/go.23.00219 | PMID 38207247 Get It

Radiation therapy (RT) is an essential part of the multidisciplinary treatment of pediatric cancer. Over the past five decades, significant advances have been made in the delivery of RT, with better dose delivery to disease targets while minimizing exposure to nearby organs at risk. These advances have led to improved treatment outcomes, increased survival, and reduced treatment-related toxicities. Advanced treatment techniques, however, require significant investment in infrastructural and personnel resources. This review documents what is currently available regarding expertise and infrastructure for pediatric radiation oncology practice in Nigeria. It was performed to serve as a foundation for the creation and design of tailored solutions (initiatives and policies) to increase pediatric radiation availability, accessibility, and equity in Nigeria and ultimately improve pediatric cancer treatment outcomes in the region.
We Shape Our Tools and Then Our Tools Shape Us: OPAT and the EHR
Rivera, Christina G. , Rivera, Christina G

Open Forum Infectious Diseases | January 11, 2024 | Volume: 11 | Issue: 2 | Pages: No page available

10.1093/ofid/ofae006 | PMID 38356783 Get It

A commentary on Canterino et al. (2024) and Munsiff et al. (2024), articles where clinicians from two large OPAT programs
Bronchoscopy-guided Cryotherapy for Airway Obstruction from Bronchial Cast
Ojard, Michelle, S, Y, Sanghavi, Devang , Yarrarapu, Siva Naga S. , Ojard, Michelle M, Tucker, Lauren K N, Sanghavi, Devang K., Yarrarapu, Siva Naga S , Guru, Pramod , Ng, Lauren

Journal of Community Hospital Internal Medicine Perspectives | January 11, 2024 | Volume: 14 | Issue: 1 | Pages: No page available

10.55729/2000-9666.1275 | PMID 38482082 Get It

The application of cryotherapy in the extraction of airway blood clots has gained increased precedence over Fogarty catheter and biopsy forceps. The cryoprobe, passed through a flexible bronchoscope, adheres and aids in the removal of foreign body through cryoadhesion within minutes. Besides blood clots, this method was found to be extremely efficient in removing different kinds of foreign bodies including food particles like peanuts, pills, and inspissated mucus.
Next-Generation Therapies for Multiple Myeloma
Bergsagel, P. Leif , Chesi, Marta , Bergsagel, P. Leif , Meermeier, Erin W.

Annual Review of Cancer Biology | January 11, 2024 | Volume: 8 | Issue: 1 | Pages: 351-371

10.1146/annurev-cancerbio-061421-014236 | PMID 39364307 Get It

Recent therapeutic advances have significantly improved the outcome for patients with multiple myeloma (MM). The backbone of successful standard therapy is the combination of Ikaros degraders, glucocorticoids, and proteasome inhibitors that interfere with the integrity of myeloma-specific superenhancers by directly or indirectly targeting enhancer-bound transcription factors and coactivators that control expression of MM dependency genes. T cell engagers and chimeric antigen receptor T cells redirect patients’ own T cells onto defined tumor antigens to kill MM cells. They have induced complete remissions even in end-stage patients. Unfortunately, responses to both conventional therapy and immunotherapy are not durable, and tumor heterogeneity, antigen loss, and lack of T cell fitness lead to therapy resistance and relapse. Novel approaches are under development to target myeloma-specific vulnerabilities, as is the design of multimodality immunological approaches, including and beyond T cells, that simultaneously recognize multiple epitopes to prevent antigen escape and tumor relapse.
Patterns of progression after immune checkpoint inhibitors for Hodgkin lymphoma: implications for radiation therapy
Burlile, Jessica F. , Frechette, K.M., Breen, William G. , Hwang, Steven R. , Nedved, Adrienne, Harmsen, William S. , Pulsipher, Sydney , Witzig, Thomas E. , Micallef, Ivana N. , Thanarajasingam, Gita , Johnston, Patrick B. , Inwards, David J. , Peterson, Jennifer , Stish, Bradley J. , Rule, William G., Ansell, Stephen M. , Witzig, T.E. , Frechette, Kelsey M, Higgins, Alexandra S, Nedved, Adrienne N, Pulsipher, Sydney D , Hoppe, Bradford S , Bennani, N Nora , Peterson, Jennifer L , Lester, Scott C. , Burlile, Jessica , Hwang, Steven R , Higgins, Alexandra , Hoppe, Bradford S. , Habermann, Thomas M. , Bennani, N. Nora

Blood Advances | January 11, 2024 | Volume: 8 | Issue: 5 | Pages: 1250-1257

10.1182/bloodadvances.2023011533 | PMID 38206755 Get It

Abstract Immune checkpoint inhibitors (ICIs) have demonstrated remarkable response rates in relapsed or refractory Hodgkin lymphoma (HL). Still, most patients eventually progress. Patterns of progression after ICIs are not well described and are essential to defining the role of local therapies in combination with ICIs. We identified patients who received ICIs for HL between 2013 and 2022. Fludeoxyglucose-18 positron emission tomography (FDG-PET) before initiating ICI and at progression on/after ICI were reviewed, and areas of active HL were recorded. An exploratory analysis of treatable progression included patients with ≤5 sites of disease on pre-ICI FDG-PET and progression only at pre-ICI sites. Ninety patients were identified; 69 had complete records, and of these, 32 (52%) had relapsed at ICI initiation, 17 (25%) were refractory, and 16 (23%) received ICI as first-line therapy. Forty-five of 69 patients had ≤5 sites of disease (limited) on pre-ICI FDG-PET. Patients with &gt;5 sites of disease had a higher risk of progression, and every site of disease &gt;5 sites conferred an additional 1.2x higher chance of progression. At a median follow-up of 4.0 years, 41 of 69 patients had progressed on/after ICIs (cumulative incidence 66.4%), and of these, 22 of 41 patients progressed only at pre-ICI sites (cumulative incidence 39.4%). In an exploratory analysis, the cumulative incidence of a treatable progression among 45 patients with limited disease was 34%. The cumulative incidence of any progression among this cohort was 58.9%. More than one-third of patients with limited disease before ICIs experienced progression only at pre-ICI sites of disease. These patients could be candidates for radiation during or after ICIs.
Efficacy and safety of biologics in primary sclerosing cholangitis with inflammatory bowel disease: A systematic review and meta-analysis
Shah, Ayesha , Jones, Michael P., Callaghan, Gavin , Fairlie, Thomas, Ma, Xiaomin, Stuart, Katherine , Cruz, Peter De , O’Beirne, James , Holtmann, Gerald , Jones, Michael , Holtmann, Gerald J , Jones, Michael P , Jones, Michael P., Culver, Emma , Tabibian, James H. , Dignass, Axel , Canbay, Ali , Gores, Gregory J.

Hepatology Communications | January 11, 2024 | Volume: 8 | Issue: 1 | Pages: No page available

10.1097/hc9.0000000000000347 | PMID 38206197 Get It

Background: Primary sclerosing cholangitis (PSC) is an immune-mediated, chronic cholestatic liver disease. Currently, liver transplantation is the only established life-saving treatment. Several studies have evaluated the effect of different biologic therapies on PSC with inconclusive findings. We conducted a systematic review and meta-analysis to assess the effects of biologics in PSC and associated inflammatory bowel disease (IBD). Methods: MEDLINE, Scopus, and Embase were searched up to July 31, 2023, for studies reporting the effects of biologics in patients with PSC-IBD. Effects of biologic therapy on alkaline phosphatase, total bilirubin, ulcerative colitis response score, and adverse events were calculated and expressed as standardized difference of means (SMD), proportions, and 95% CI using a random-effects model. Results: Six studies, including 411 PSC-IBD patients who received biologics, were included. Biologic treatment was associated with no change in alkaline phosphatase (SMD: 0.1, 95% CI: −0.07 −0.17, p=0.43), but a small and statistically significant increase in total bilirubin (SMD: 0.2, 95% CI: 0.05–0.35, p<0.01). 31.2% (95% CI: 23.8–39.7) of patients with IBD achieved endoscopic response, and there was a significant improvement in ulcerative colitis response score (SMD: −0.6,95% CI: −0.88 to 0.36, p<0.01). Furthermore, 17.6% (95% CI: 13.0–23.5) of patients experienced adverse events severe enough to discontinue therapy, and 29.9% (95% CI: 25.2–34.8) had a loss of response to biologics. Conclusions: Treatment of patients with PSC-IBD with biologics (vedolizumab, infliximab, and adalimumab) was not associated with improvement of biochemical markers of cholestasis. Biologics are effective in treating the colitis associated with PSC. Vedolizumab was associated with worsening liver enzymes in contrast to other biologics, a finding that warrants further study.